Pfizer ends Trillium-related development as R&D spend jumps

May 5, 2026 10:41 AM EDT R&DPharma Pfiz­er cuts fi­nal Tril­li­um-re­lat­ed pro­gram, but R&D spend jumps on can­cer, obe­si­ty stud­ies Max Bayer Senior Reporter Pfiz­er has dis­con­tin­ued the fi­nal clin­i­cal study stem­ming from its 2021 ac­qui­si­tion of Tril­li­um Ther­a­peu­tics, fun­nel­ing cash pri­mar­i­ly to­ward a host of oth­er can­cer and … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER